by Portfolio Grader | September 28, 2012 7:30 pm
The grades of seven Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Novartis (NYSE:NVS) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Novartis manufactures pharmaceutical and consumer healthcare products. The stock has a dividend yield of 2.5%. Shares of the company are up 3.6% from a month ago. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Eli Lilly (NYSE:LLY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The stock price has risen 6.8% over the past month, better than the 2.6% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of LLY stock.
Merck (NYSE:MRK) is seeing ratings go up from a B last week to an A this week. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. Shares of MRK are up 5.1% from a month ago. This is better than the S&P 500′s 2.6% increase over the same period. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Pfizer (NYSE:PFE) shows solid improvement this week. The company’s rating rises from a B to an A. Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The price of PFE has increased 4.5% over the past month. For more information, get Portfolio Grader’s complete analysis of PFE stock.
SciClone Pharmaceuticals (NASDAQ:SCLN) earns a B this week, jumping up from last week’s grade of C. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. Wall Street has pushed the stock higher by 11.9% over the past month. The stock has a trailing PE Ratio of 7.9. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
This is a strong week for Lannett Co. (AMEX:LCI). The company’s rating climbs to B from the previous week’s C. Lannett manufactures and distributes pharmaceutical products under its own trade name and under generic names. Over the last month, the price of LCI shot up 1.8%. For more information, get Portfolio Grader’s complete analysis of LCI stock.
Acura Pharmaceuticals (NASDAQ:ACUR) boosts its rating from a C to a B this week. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Investors have pushed the stock price up 9.1% over the past month. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/09/7-pharmaceutical-stocks-to-buy-now-nvs-lly-mrk/
Short URL: http://investorplace.com/?p=238625
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.